CAR-M: First Therapeutic Application

Our first programs apply our lead LNP identified with the RAPTOR platform to monocyte and macrophage reprogramming using chimeric antigen receptor macrophages (CAR-M).

Monocytes are a type of white blood cell that circulate in the bloodstream and differentiate into other immune cells such as macrophages and dendritic cells. They’re part of the innate immune system, acting as rapid responders to infection, tissue damage, and inflammatory signals.

Macrophages are professional effector cells with intrinsic access to immune and tissue niches, including the bone marrow, lymphoid organs, and sites of inflammation. By equipping these cells with chimeric antigen receptors, CAR-M enables antigen-directed recognition and elimination of disease-driving cell populations.

This shared mechanistic foundation underpins both our oncology and autoimmune programs.

Advancing With Scientific Discipline

Our clinical programs are designed to rigorously evaluate:

• Selectivity of targeted cell depletion
• Durability of immune re-programming
• Safety of the treatment

These studies define both the initial therapeutic potential and future applications of the platform.